What is Huma?
Huma is a global healthcare technology company specializing in AI-driven digital health platforms. Its cloud-based solutions cater to hospitals, life sciences organizations, and health systems, enabling critical functions such as remote patient monitoring, clinical research, virtual care, and data-driven decision-making. By enhancing healthcare delivery and patient outcomes worldwide, Huma is at the forefront of digital transformation in the health sector.
How much funding has Huma raised?
Huma has raised a total of $296M across 5 funding rounds:
Series A
$28M
Series B
$25M
Series C
$130M
Private Equity
$33M
Series D
$80M
Series A (2018): $28M with participation from NWS Holdings
Series B (2019): $25M led by Bayer
Series C (2021): $130M supported by Nikesh Arora, Hitachi Ventures, Sony Innovation Fund, Unilever Ventures, Michael Diekmann, Samsung Next, Leaps by Bayer, and HAT Technology & Innovation Fund
Private Equity (2022): $33M featuring AstraZeneca
Series D (2024): $80M backed by AstraZeneca and Hitachi Ventures
Key Investors in Huma
AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca is based in the United Kingdom.
Hitachi Ventures
Hitachi Ventures GmbH is a corporate venture firm that partners with ambitious founders to drive world-changing innovations across four core themes: Digital, Industrial, Environment, and Healthcare. With over $1 billion in assets under management, the company leverages Hitachi's global power to support visionary entrepreneurs in building intelligent infrastructure, sustainable productivity, and advanced healthcare solutions.
Bayer
Bayer is a global enterprise in the life science fields of healthcare and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. They have divisions in pharmaceuticals, crop science, animal health, and consumer health. Bayer is headquartered in Leverkusen, Germany.
What's next for Huma?
With its latest major strategic investment, Huma is poised for accelerated growth and further innovation in the digital health space. The substantial capital raised, particularly in its Series D round, suggests a focus on scaling operations, expanding market reach, and advancing its AI capabilities. This enterprise-level funding will likely fuel the development of new platform features, strategic partnerships, and global expansion initiatives, solidifying Huma's position as a leader in transforming healthcare delivery through technology.
See full Huma company page
